James Love's blog
The 2012 WIPO/Library of Congress International Copyright Training symposium for developing countriesSubmitted by James Love on 21. March 2012 - 9:29
This week WIPO and the Library of Congress are holding a week long symposium on International Copyright, with title:
Emerging Issues in Copyright and Related Rights for Developing
Countries and Countries with Economies in Transition
the World Intellectual Property Organization (WIPO)
in cooperation with
the United States Copyright Office, Library of Congress
Washington D.C., March 19 to 23, 2012
KEI Statement on India's granting of compulsory license to patents on cancer drug sorafenib (NATCO Vs. BAYER)Submitted by James Love on 12. March 2012 - 2:40
The India Controller General Controller General of Patents, Designs & Trade Marks has just (March 12, 2012) issued an order granting a compulsory license to patents on the cancer drug sorafenib/Nexavar, in the matter of NATCO Vs. BAYER. A copy of the decision is attached below.
This is a blog about the Anti-Counterfeiting Trade Agreement (ACTA). More information is available here: http://keionline.org/acta
ACTA is an attempt to bypass multilateral institutions
IIPA Special 301 complaints regarding unauthorized copying of textbooks and other educational materialsSubmitted by James Love on 25. February 2012 - 17:54
USTR asked to use trade pressure to curtail unauthorized copying of educational materials
Every year, USTR publishes the names of countries that do not adequately protect intellectual property rights. (See http://keionline.org/ustr/special301) . Among the classifications are the Priority Watch List (PWL) and the somewhat lower status Watch List (WL).
President Obama claims to have kept "lobbyists" off the advisory boards for USTR. The Obama Administration relies upon the narrow legal definition of those persons who register to lobby the US Congress, which excludes expenditures to direct, supervise or support the lobbyists, and expenditures of many staff and consultants who are not fully engaged in lobbying the Congress. Expenditures to influence the executive branch (including USTR) has very little if any regulation, and are not counted as lobbying.
In a meeting with USTR on February 15, 2012, KEI, MSF, Oxfam and Public Citizen pressed USTR to release the negotiating text for the intellectual property rights chapter in the TPPA trade agreement negotiation. USTR said the negotiation had "unprecedented" transparency, but maintained the text needed to be secret from the general public. USTR also claimed than no one on its many advisory boards, who are cleared to see the negotiating text, were lobbyists.
U.S. Dept of Commerce asked to review Africa Intellectual Property Forum compliance w/ Executive Order 13155Submitted by James Love on 10. February 2012 - 12:53
Health GAP, KEI, Oxfam, Public Citizen, Universities Allied for Essential Medicines and Professor Susan Sell have written Cameron Forbes Kerry, the General Counsel for the U.S. Department of Commerce, asking Kerry to "review work on the Africa Intellectual Property Forum, currently scheduled for April 3-5, 2012 in Cape Town, South Africa, to see if the sponsorship of the event violates Executive Order 13155, on Access to HIV/AIDS Pharmaceuticals and Medical Technologies." Executive Order 13155 was issued by President Clinton on May 10, 2000 after an extensive review of U.S.
On December 16, 2011, H.R. 3699, "the Research Works Act", was introduced by Rep. Darrell Issa (R-CA), Chairman of the Committee on Oversight and Government Reform, and Committee member Rep. Carolyn Maloney (D-NY). This is how the Association of American Publishers describes the bill:
On June 11, 2011, KEI published KEI Policy Brief 2011:1, which was titled: "White House and European Commission trade official oppose waiver of drug patents for Least Developed Countries (LDCs)."
According to OpenSecrets.Org, the pharmaceutical manufacturing sector has reported $115,571,832 in lobbying for 2011, a number that will grow considerably when all quarterly reports are filed. The top lobbying outlays were reported by PhRMA, the trade association, followed by Pfizer, Amgen, Merck, Lilly, Novartis, Bayer and GSK. The top generic company was Teva, which ranked 12th overall. As reported by OpenSecrets, some firms are listed more than once, for lobbying outlays by different subsidiaries.
On November 13, 2011, the Los Angeles Times published a story by David Willman on a no-bid contract with the Department of Health and Human Services (DHHS) to supply the government with a drug for smallpox. The LA Times story begins with this:
Over the last year, the Obama administration has aggressively pushed a $433-million plan to buy an experimental smallpox drug, despite uncertainty over whether it is needed or will work.
Special 301 on steroids? Section 205 of HR 3261, the Stop Online Piracy Act (SOPA) is not just about the InternetSubmitted by James Love on 7. November 2011 - 10:46
On October 26, 2011, a bipartisan group of members of the U.S. House of Representatives introduced HR 3261, the Stop Online Piracy Act, known as SOPA. While much of the bill deals with "online" piracy," some sections of the bill appear to have nothing to do with the Internet. The bill also creates a new bureaucracy to deal with very broadly defined trade related intellectual property rights issues, including those identified in the annual USTR Special 301 report.